Advanced search

Antiarrhythmic drugs management in patients with atrial fibrillation: the new guidelines

(2011) MINERVA CARDIOANGIOLOGICA. 59(2). p.187-195
Author
Organization
Abstract
Antiarrhythmic drug therapy will continue to play an important role in the treatment of atrial fibrillation (AF). Pharmacological therapy is focused on AF symptom relief and on prevention of tachycardiomyopathy. The choice between the various anti-arrhythmic drugs available, either for rate or rhythm control, mainly depends on the underlying cardiac disease, type of AF and possible side-effects. New anti-arrhythmic drugs in the guidelines - vernakalant and dronedarone - are promising, but further research is required to explore their role in treatment of patients with AF. In this review, we will discuss the role of antiarrhythmic drugs in management of patients with AF according to the new AF guidelines of the European Society of Cardiology.
Keywords
Atrial fibrillation, Anti-arrhythinic agents, Guidelines as topic, LONG-QT-SYNDROME, SINUS RHYTHM, RECENT-ONSET, CONVERSION EFFICACY, IMMEDIATE CARDIOVERSION, INTRAVENOUS FLECAINIDE, CARDIAC-SURGERY, DE-POINTES, IBUTILIDE, FLUTTER

Citation

Please use this url to cite or link to this publication:

Chicago
Haitsma, DB, NMS De Groot, and Luc Jordaens. 2011. “Antiarrhythmic Drugs Management in Patients with Atrial Fibrillation: The New Guidelines.” Minerva Cardioangiologica 59 (2): 187–195.
APA
Haitsma, D., De Groot, N., & Jordaens, L. (2011). Antiarrhythmic drugs management in patients with atrial fibrillation: the new guidelines. MINERVA CARDIOANGIOLOGICA, 59(2), 187–195.
Vancouver
1.
Haitsma D, De Groot N, Jordaens L. Antiarrhythmic drugs management in patients with atrial fibrillation: the new guidelines. MINERVA CARDIOANGIOLOGICA. 2011;59(2):187–95.
MLA
Haitsma, DB, NMS De Groot, and Luc Jordaens. “Antiarrhythmic Drugs Management in Patients with Atrial Fibrillation: The New Guidelines.” MINERVA CARDIOANGIOLOGICA 59.2 (2011): 187–195. Print.
@article{8135565,
  abstract     = {Antiarrhythmic drug therapy will continue to play an important role in the treatment of atrial fibrillation (AF). Pharmacological therapy is focused on AF symptom relief and on prevention of tachycardiomyopathy. The choice between the various anti-arrhythmic drugs available, either for rate or rhythm control, mainly depends on the underlying cardiac disease, type of AF and possible side-effects. New anti-arrhythmic drugs in the guidelines - vernakalant and dronedarone - are promising, but further research is required to explore their role in treatment of patients with AF. In this review, we will discuss the role of antiarrhythmic drugs in management of patients with AF according to the new AF guidelines of the European Society of Cardiology.},
  author       = {Haitsma, DB and De Groot, NMS and Jordaens, Luc},
  issn         = {0026-4725},
  journal      = {MINERVA CARDIOANGIOLOGICA},
  keywords     = {Atrial fibrillation,Anti-arrhythinic agents,Guidelines as topic,LONG-QT-SYNDROME,SINUS RHYTHM,RECENT-ONSET,CONVERSION EFFICACY,IMMEDIATE CARDIOVERSION,INTRAVENOUS FLECAINIDE,CARDIAC-SURGERY,DE-POINTES,IBUTILIDE,FLUTTER},
  language     = {eng},
  number       = {2},
  pages        = {187--195},
  title        = {Antiarrhythmic drugs management in patients with atrial fibrillation: the new guidelines},
  volume       = {59},
  year         = {2011},
}

Web of Science
Times cited: